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Abstract
Aims: To critically appraise, compare and synthesise the quality and acceptability of multi-item patient reported
outcome measures for adults with chronic or episodic headache.
Methods: Systematic literature searches of major databases (1980–2016) to identify published evidence of PROM
measurement and practical properties. Data on study quality (COSMIN), measurement and practical properties per
measure were extracted and assessed against accepted standards to inform an evidence synthesis.
Results: From 10,903 reviewed abstracts, 103 articles were assessed in full; 46 provided evidence for 23 PROMs: Eleven
specific to the health-related impact of migraine (n¼ 5) or headache (n¼ 6); six assessed migraine-specific treatment
response/satisfaction; six were generic measures. Evidence for measurement validity and score interpretation was
strongest for two measures of impact, Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) and Headache
Impact Test 6-item (HIT-6), and one of treatment response, the Patient Perception of Migraine Questionnaire
(PPMQ-R). Evidence of reliability was limited, but acceptable for the HIT-6. Responsiveness was rarely evaluated.
Evidence for the remaining measures was limited. Patient involvement was limited and poorly reported.
Conclusion: While evidence is limited, three measures have acceptable evidence of reliability and validity: HIT-6, MSQ
v2.1 and PPMQ-R. Only the HIT-6 has acceptable evidence supporting its completion by all ‘‘headache’’ populations.
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Background
Headache disorders are common in the adult popula-
tion; the most common – tension-type and migraine –
have a one-year prevalence of 40% and 11%
respectively (1,2,3). Between 2–4% of the general popu-
lation experience chronic headache (4,5). Headache dis-
orders can profoundly impact an individual’s
functional ability and quality of life (3,6). Aﬀecting
primarily young adults, the personal and economic
burden of headache is substantial and comparable to
other chronic conditions such as congestive heart fail-
ure, hypertension, or diabetes (7).
An individual’s self-report of the presence, severity,
frequency, and impact of headache is crucial to under-
standing the eﬀectiveness of therapeutic interventions.
Patient-reported outcome measures (PROMs), which
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seek to provide a patient-based assessment of the
impact of headache on how people feel, function and
live their lives, are now available. While recommenda-
tions to include PROMs in headache clinical trials are
available (8,9), speciﬁc guidance for PROM-based
outcome reporting does not exist. The integrity of
PROM-based reporting is underpinned by clear evi-
dence of essential measurement and practical properties
in the clinical population of interest (10,11). It cannot
be assumed that the reliability and validity of measure
is consistent across diﬀerent types of headache, and
evidence of PROM performance across diﬀerent sub-
types is often not available (12). PROM score interpret-
ation also requires guidance for what change in score
reﬂects a meaningful change in ‘‘headache’’ for the
individual patient (minimal important change (MIC))
and what diﬀerence reﬂects a meaningful diﬀerence
between groups of patients deﬁned by some external
anchor (minimal important diﬀerence (MID)) (10,11).
Structured reviews of PROM performance provide
essential evidence to inform the selection of robust,
relevant, and acceptable measures.
In this systematic review, we critically appraise, com-
pare and synthesise published evidence of essential
measurement and practical properties for clearly
deﬁned PROMs evaluated in adult headache popula-
tions. The review provides a transparent summary
of the evidence base with which to inform PROM
selection for future application in headache-speciﬁc
research.
Methods
Identification of studies and PROMs: Search
strategy
The search strategy was developed by experienced
reviewers (KH, TM, RP, SP) and with expert librarian
support to retrieve references relating to the develop-
ment and/or evaluation of multi-item PROMs used in
the assessment of adults (aged 18 years and above) with
chronic or episodic headache including migraine.
Medical subject headings (MeSH terms) and free
text searching were used to reﬂect three characteristics:
a) population – headache and migraine; b) type of
assessment – patient-reported outcome measures
(PROMs); and c) measurement and practical properties
(11,13,14). The full search strategy is available in
Appendix 1.1.
Two databases were searched (MEDLINE (OVID),
EMBASE (OVID); 1980 to December 2016) (Figure 1).
A subsequent search incorporated the names of more
than 50 multi- and single-item measures identiﬁed
during the initial search (Appendix 1.2 and 1.3).
From a total of 39 multi-item PROMs thus identiﬁed,
16 had been superseded by revised measures or were no
longer in use, as evidenced by their lack of inclusion in
studies published post 2000 (Appendix 2). Given that
such measures are unlikely to be of interest, the eligi-
bility criteria for the review and analysis was revised to
focus on PROMs in use post-2000.
The citation lists of included articles and existing
reviews were also reviewed (15,16). Named author
searches were conducted.
Inclusion/exclusion criteria
Titles and abstracts of all articles were independently
assessed for inclusion/exclusion by two reviewers (TM,
KH) and agreement checked. Published articles were
included if they provided evidence of development/
evaluation for clearly deﬁned, reproducible, multi-
item PROMs, following self-completion by adults
who self-reported or had been diagnosed by a clinician
as having a headache disorder. Articles relating solely
to the application of measures without some evidence
of measurement and/or practical properties were
excluded. Articles describing the translation of
PROMs and/or evaluations in non-English speaking
populations were also excluded. Conference papers
and abstracts were excluded.
Included PROMs had to be in use in research pub-
lished between 2000–2016. PROMs were categorised as:
Generic (proﬁle; utility) or condition-speciﬁc (head-
ache; migraine). Clinician-reported, diagnostic and
screening measures were excluded. Domain-speciﬁc
measures that were not speciﬁc to the impact of head-
ache, and measures that were not clearly reproducible,
were excluded.
Data extraction and appraisal
A data extraction form was informed by guidance for
PROM evaluation (10,11,17), published PROM
reviews (14,18,19) and the COnsensus-based
Standards for the selection of health Measurement
Instruments (COSMIN) checklist (20,21). The form
captured both study and PROM-speciﬁc information.
Population diagnosis and diagnostic criteria (if any)
were extracted. We sought evidence on: Reliability
(internal consistency; test–retest, intra/inter-tester); val-
idity (content; construct; known groups); responsive-
ness; interpretation (minimal important change (MIC)
and/or diﬀerence (MID)); and precision (data quality;
end eﬀects). Evidence for the practical properties
included acceptability (relevance; respondent burden)
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and feasibility. Evidence of active patient involvement
in PROM evaluation was also sought (18,22,23).
All publications were double-assessed (KH, TM) and
agreement checked.
Assessment of study methodological quality
One experienced reviewer (KH) applied the COSMIN
checklist to assess the methodological quality of
included studies (20,21). Methodological quality was
evaluated per measurement property on a four-point
rating scale (excellent, good, fair, poor) and determined
by the lowest rating of any items in each checklist sec-
tion (21).
Assessment of PROM quality
A similar checklist for PROM quality does not exist.
Therefore, a pragmatic checklist informed by a synthe-
sis of various recommendations was adopted
(18,19,21,24) (Appendix 3: Table 2). To provide a
global overview of the concepts captured within the
reviewed headache-speciﬁc measures, items were cate-
gorised as per the domains of one of the most fre-
quently used conceptual models of health-related
quality of life (HRQOL) – the Ferrans revision to the
Wilson and Cleary model (25,26).
Data synthesis
A qualitative synthesis of evidence per reviewed PROM
per reported measurement property informed the over-
all judgement of quality and acceptability. The synthe-
sis combined four factors: a) study methodological
quality (COSMIN scores); b) number of studies report-
ing evidence per PROM; c) results per measurement
property (Appendix 3: Table 2); and d) evidence of
consistency between evaluations (23,27). Two elements
of the data synthesis are described: First, the overall
quality of a measurement property was reported as
adequate (þ), conﬂicting (), inadequate (), or inde-
terminate (?). Second, evidence for the overall quality of
evidence was categorised as ‘‘strong’’, ‘‘moderate’’,
‘‘limited’’, ‘‘conﬂicting’’, or ‘‘unknown’’ (27).
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Figure 1. Review of measures used with people with headache – PRISMA flow diagram for article selection (search conducted 1980
to December 2016).
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Results
Identification of studies and PROMs
Study and PROM identiﬁcation is summarised per
PRISMA guidance in Figure 1 (www.prisma-state-
ment.org). Forty-six articles provided evaluative evi-
dence for 23 PROMs (Appendices 4 and 5 (Tables 3
and 4)). Six assessed impact of headaches overall: The
EUROLIGHT (28); Headache Activities of Daily
Living Index (HADLI) (29); Headache-speciﬁc
Disability Questionnaire (HDQ) (30); the Headache
Impact Test (HIT) (3) and its short-form HIT-6 (31);
and a headache-speciﬁc modiﬁcation of the Short-
Form 36-item Health Survey (32). Five were speciﬁc
to the impact of migraine: Functional Assessment in
Migraine questionnaire (FAIM) (33); Headache
Needs Assessment Survey (HANA) (34); MIgraine
Disability ASessment (MIDAS) (35); Migraine-
Speciﬁc Quality of Life Questionnaire (MSQ v2.1)
(36); and the Migraine-Speciﬁc Quality of Life
(MSQOL) measure (37). Six assessed response to and/
or satisfaction with migraine-speciﬁc drug treatment:
Completeness of Response to migraine therapy
(CORS) (38); Migraine Assessment of Current
Therapy (Migraine-ACT) (39); Migraine-Treatment
Assessment Questionnaire (M-TAQ) (40); Migraine-
Treatment Optimisation Questionnaire (M-TOQ) (41);
Migraine Treatment Satisfaction Measure (MTSM)
(42); and the Patient Perception of Migraine
Questionnaire – Revised (PPMQ-R) (43). Item content
of all speciﬁc measures is illustrated in Appendix 6
(Table 5).
Finally, six generic measures had been assessed in
headache populations: The Short-Form 36-item
Health Survey (SF-36) (44), SF-12 (45), SF-8 (46),
EuroQoL EQ-5D 3L (47), Health Utility Index-3
(HUI-3) (48) and the Quality of Well-being Scale
(QWB) (49,50).
Patient and study characteristics
(Appendix 5 (Table 4))
Patient populations ranged from 18 to 83 years, were
largely white, often with large proportions of female
participants. Sample sizes ranged from 25 to more
than 8,500. Populations included mixed, chronic,
and/or episodic headache or migraine. Where clini-
cian-based diagnosis was described, most adopted
the International Classiﬁcation of Headache
Disorders (ICHD-II), available at http://www.ihs-klas-
siﬁkation.de/en/. However, for many, patients were
self-diagnosed, and a wide range of diagnostic criteria
were described. Most studies were cross-sectional or
longitudinal surveys. Nine were clinical trials or invol-
ving data secondary analysis. Fourteen studies were
speciﬁc to PROM development and/or initial evalu-
ations. Most evaluations were with US populations.
Measurement properties and methodological
quality
Study methodological quality per measurement prop-
erty per reviewed PROM is presented in Appendix 7
(Table 6). The overall evidence synthesis is presented
in Table 1.
PROMs assessing migraine and headache-speciﬁc impact
(n¼ 11)
Apart from the FAIM, MSQ v2.1, MSQoL and
HIT, all measures lack a clear description of aim, the
concepts being measured, or the process of item gener-
ation. The FAIM (33), MSQ v2.1 (36) and MSQoL (37)
involved expert clinicians and patients in item gener-
ation, supporting a positive rating of content validity.
The HIT ‘‘item bank’’ was informed by four legacy
measures – the MIDAS, MSQ (v1.0), Headache
Disability Index (HDI) and Headache Impact
Questionnaire (HIMQ) – and consultation with clin-
icians (3). Apart from the MSQ, item generation for
these measures is poorly reported but largely driven
by clinical opinion. Additional evaluations of the con-
tent validity of the item bank or short form measures is
not described. Clinical opinion, literature review, and/
or the completion of established questionnaires were
the main sources of items for the remaining measures.
There was no evidence of active patient collaboration in
PROM development and/or evaluation.
The shortest measures are the MIDAS (ﬁve items)
and HIT-6 (six items); the longest is the 103-item
EUROLIGHT (Table 2). Apart from the FAIM, all
assess headache/migraine symptomology. While ﬁve
headache-speciﬁc measures assess pain, the migraine-
speciﬁc measures do not. Only the HANA, MSQv2.1
and HIT-6 assess fatigue.
All assess the impact of headache/migraine on social
function, activities of daily living and/or work. Seven –
FAIM, HANA, MSQv2.1, MSQOL, HIT, HIT-6, and
EUROLIGHT – assess the emotional burden of head-
ache/migraine; ﬁve of these – FAIM, MSQv2.1, HIT,
HIT-6, and EUROLIGHT – plus the HADLI, assess
the impact on cognition and diﬃculty with thinking.
Acceptable evidence of measurement dimensionality
from studies of at least moderate methodological qual-
ity was reviewed for ﬁve measures – FAIM (33),
MSQv2.1 (12,51), MSQoL (52), HIT (3), HIT-6 (53);
three have moderate to strong evidence of both struc-
tural validity and internal consistency – FAIM (33),
MSQ v2.1 (12,36,51,54) and the HIT-6
(31,41,53,55,56) (Table 1; Appendix 7). Three measures
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have acceptable evidence of the reliability of internal
consistency from studies of at least moderate methodo-
logical quality, supporting application in the assess-
ment of groups (FAIM) (33) and individuals (MSQ
v2.1 [12,36,51], HIT-6 [53,56]) (Table 1; Appendix 7);
however, for the majority, evidence was limited (n¼ 3),
from poor quality studies (n¼ 3) or not available
(n¼ 1). Only the HIT (31,57) and HIT-6 (31,53,56,57)
have acceptable evidence of temporal stability support-
ing application in the assessment of groups and indi-
viduals. Evidence for the remaining measures was
limited.
Five measures have acceptable evidence from good
quality studies describing their construct validity –
FAIM (33), MIDAS (56), MSQ v2.1 (12,36,43,53),
HIT (57) and HIT-6 (12,53,56,57). For the remaining
measures, evidence was of poor quality (n¼ 4) or not
available (n¼ 2); authors often failed to hypothesise a
priori the association between variables.
Evidence of responsiveness was limited. Statistically
signiﬁcant between-group diﬀerences for average HIT-6
and total HIT change scores were reported for patients
categorised by self-reported change (better/same/worse)
in physical activity, level of frustration or daily activ-
ities following a three-month follow-up period of
‘‘usual care’’ (31).
Large and moderate eﬀect size statistics were
reported for the MSQv2.1 (12) and HIT-6 (53) in
patients who reported large or moderate improvement
in the number of headache days following a pharma-
ceutical-based clinical trial, respectively. Following a
non-comparative, observational study of zolmitriptan
for an acute migraine attack, small and moderate ES
statistics were reported for the SF-36 and MSQoL
respectively (52).
Following completion of the HIT-6 by patients with
chronic daily headache in a trial of usual medical care
(UMC) versus UMC plus acupuncture, an anchor-
based estimate of the MIC was calculated as approxi-
mately 3.7; the MID was estimated as 2.3 (58). Change
in HIT-6 scores that exceeded the proposed MIC were
reported in patients with chronic migraine receiving
onabotulinumtoxinA in a placebo-controlled double
blind trial; a between-group diﬀerence that exceeded
the MID, in favour of the active treatment, was also
reported (59).
Both anchor-based (60,61) and distribution-based
estimates (60) were calculated for the MSQv2.1 follow-
ing completion by patients with chronic migraine. Cole
et al. (60) proposed an MIC of 5.0 for the RR domain,
with ranges for the RP (5.0 to 7.9) and EF (range 8.0 to
10.6) domains; MIDs were recommended as RR 3.2,
RP 4.6, EF 7.5 (60). A between-group diﬀerence that
exceeded the proposed MID, in favour of the active
treatment, was reported for the MSQv2.1 RR domain
only in patients with chronic migraine receiving
onabotulinumtoxinA in a placebo-controlled double
blind trial (59). However, within-individual change
scores were larger than the proposed MIC for each
domain for patients receiving active treatment.
PROMs assessing response to or satisfaction with
migraine-speciﬁc treatment (six measures)
Four of the six measures – the CORS, M-TOQ,
MTSM and PPMQ-R – have acceptable descriptions
of the measurement aim, conceptual underpinning
and item generation. Although detail is limited, three
measures – CORS, MTSM and PPMQ-R – involved
both expert clinicians and patients in item generation
(the MTSM involved US and UK participants), sup-
porting a positive rating of content validity; the
M-TAQ utilised patient interviews and focus groups,
with additional reference to established treatment opti-
misation measures.
Item generation for the M-ACT (39) and the
M-TOQ (41) was informed by clinical evidence and
the consensus of clinical headache experts and research-
ers; patients were not involved, supporting a negative
rating of content validity. There was no evidence of
active patient collaboration.
The shortest measures are the M-ACT (four items)
and M-TOQ-5 (ﬁve items); the longest is the 45-item
MTSM (Appendix 4). Apart from the M-ACT and
M-TAQ, all assess migraine symptomology, including
pain severity, and the wider impact on activities of daily
living and/or work; the PPMQ-R also assesses limita-
tions in social functions (Appendix 6). The CORS,
M-TOQ-15 and PPMQ-R assess the emotional
burden of migraine; only the CORS and PPMQ-R
also assess cognition and diﬃculty with thinking.
Three measures assess if the patient has ‘‘returned to
normal’’ – CORS, M-ACT, and M-TOQ. All assess
conﬁdence in/or satisfaction with treatment; the
M-TOQ assesses treatment side-eﬀects.
Only the PPMQ-R has acceptable evidence of meas-
urement dimensionality and internal consistency reli-
ability from studies of at least moderate
methodological quality (Table 1; Appendix 7). For
three measures – CORS, M-TOQ, and MTSM –
evidence was acceptable but limited.
Only the M-ACT has acceptable evidence of tem-
poral stability from several studies of fair methodo-
logical quality, supporting application in the
assessment of groups (Table 1; Appendix 7). Evidence
for three measures – M-TAQ, M-TOQ, and PPMQ-R –
was limited to single studies judged to be of fair quality
(Table 1; Appendix 7). Only the PPMQ-R and MTSM
have acceptable evidence of construct validity from
good quality studies. For the remaining measures,
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evidence was limited (CORS, M-TAQ, and M-TOQ) or
from poor quality (M-ACT) studies.
Following a two-month pharmaceutical trial, small
to moderate change score correlations between the
CORS and the PPMQ-R supported a priori hypoth-
esised associations, providing acceptable, but limited,
evidence of responsiveness (38). Further criterion-
based evidence, comparing the comparative CORS
with change in CORS sub-sets at two months, provided
additional, hypothesis-driven evidence of responsive-
ness (38). Small to moderate eﬀect size statistics were
reported for the PPMQ-R in patients categorised by
self-reported improvement (range 0.14 to 0.50) or wor-
sening (range 0.06 to 0.23) in pain severity; the largest
ES were reported for the Eﬃcacy and Function
domains (43).
The Standard Error of Measurement (SEM) was
calculated for the PPMQ-R, as a reﬂection of the
within-individual minimal change in score (MIC) (43).
Apart from the Cost domain (SEM 11.0), SEM esti-
mates ranged 3.4 (Bothersome) to 5.4 (Total score),
supporting an MIC recommendation of ﬁve points for
the total score and Eﬃcacy, Function and Ease of Use
domains. Results suggest that the Cost domain is highly
variable and not responsive to change in migraine
severity or role limitation.
Estimates of the minimally important change and
minimally important diﬀerence were reviewed for
three headache-speciﬁc measures: MSQ v2.1 (36),
HIT-6 (31), PPMQ-R (43). Completion of the HIT-6
by Dutch patients with chronic tension-type headache
(62) and episodic migraine (63) suggested a wider range
of MIC values, from 2.5 (63) to 8.0 (62) than that
determined in a US population with chronic daily head-
ache (3.7) (58). The diﬀerences were largely explained
by use of diﬀerent anchors – where a greater perceived
change was the imposed anchor, a larger MIC was cal-
culated. An MIC of >8.0 suggests that improvement
must be present in at least two of the six HIT-6 items
(62), which may be judged a relevant treatment eﬀect
(62,63). Similarly, suggested MID values range from
1.5 (episodic migraine) (63) to 2.3 (chronic daily
headache) (58).
Generic PROMs (n¼ 6)
Evaluations of all generic measures in the headache
population were very limited. There was no evidence
exploring the content validity or relevance of the six
reviewed generic measures with the headache popula-
tion. There was no evidence of active patient
collaboration.
Where applicable, there was no evidence of measure-
ment dimensionality or internal consistency reliability
(Table 1). Just one measure – the QWB-SA – had
conﬂicting evidence of temporal stability from one
study, judged to be of poor methodological quality
(64) (Table 1; Appendix 7).
Acceptable evidence of construct validity from sev-
eral studies judged to be of fair or good methodological
quality was reviewed for both the SF-36 (36,55,65) and
the SF-8 (7,31,57,56); for the SF-12 evidence was
limited (Table 1; Appendix 7). For the remaining
measures, evidence was limited (EQ-5D) or of poor
quality (HUI-3, QWB). There was no evidence of
measurement responsiveness.
Discussion
High quality, relevant and acceptable PROMs provide
patient-derived evidence of the impact of headache and
the relative beneﬁt of associated healthcare at both the
time of the headache and the intervening period. The
importance of capturing the patient perspective is
reﬂected in the large number of measures included in
this review. However, apart from two condition-speciﬁc
– HIT-6 and MSQv2.1 – and one treatment-response –
PPMQ-R – measures, for which strong evidence was
reviewed, evidence was largely limited or not available.
This is the ﬁrst systematic review to include a
methodological assessment of both study and PROM
quality in the headache population. Clarity in PROM
focus is an essential, but often overlooked aspect of
PROM development (24,80). Except for four condi-
tion-speciﬁc (MSQ v2.1, MSQoL, HIT and HIT-6)
and four treatment-response measures (CORS,
M-TOQ, MTSM and PPMQ-R), all lacked a clear
description of the measurement aim. Moreover, the
condition-attribution of measures was not always self-
evident: Just three ‘migraine-speciﬁc’ measures assessed
the impact of ‘‘migraine’’ (FAIM, MSQ v2.1 and
MSQoL). The HANA includes both ‘‘migraine’’ and
‘‘headache’’ in the item stem and, despite the name,
the MIDAS assesses the impact of ‘‘headache’’. It is
suggested that the attribution of ‘‘headache’’ supports
a ‘‘broader’’ assessment than would be achieved with
‘‘migraine’’; moreover, many patients may be unaware
of a migraine diagnosis (3). The HIT item content was
informed by both migraine (MSQ and MIDAS) and
headache-speciﬁc (HIMQ, HDI) measures; a content
comparison failed to reveal any systematic diﬀerences
in concept coverage, and further evaluation in a mixed
population supported the uni-dimensionality of head-
ache disability (3). Evidence further supports the ability
of the HIT to assess headache disability across a wide
spectrum of impact, avoiding the potential for ceiling
eﬀects, following completion by headache and migraine
populations (3,63). Just four measures (the HIT-6,
HADLI, HDQ and MIDAS) have been evaluated in
both headache and migraine populations. However,
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while evidence is strong for the HIT-6, the remaining
measures should be applied with caution.
Except for two condition-speciﬁc (MSQv2.1 and
MSQoL) and four treatment-response measures
(CORS, M-TAQ, MTSM and PPMQ-R), the extent
of patient participation was limited and poorly detailed.
Moreover, except for three measures (MSQoL,
PPMQ-R and EUROLIGHT) PROM relevance, con-
tent and face validity was not explicitly explored with
patients and/or expert panels. Item content for the
remaining measures was informed by a mix of qualita-
tive research with clinicians, reference to existing
measures, published literature and/or completed ques-
tionnaires. Successful treatment for headache disorders
should seek to improve both overall quality of life, as
well as an individual’s quality of life during the attack
(37); assessment should seek to capture these
distinctions.
Although varying in length, there was a similarity of
item content across condition-speciﬁc measures. Most
assessed headache/migraine-related symptomology;
pain severity was commonly assessed by headache-spe-
ciﬁc and treatment-response measures, but not by the
migraine-speciﬁc measures. Just two measures
(MSQv2.1 and HIT-6) assessed fatigue. Measures
with a primary focus on symptomology have been
criticised for failing to take into consideration the
longer-term consequence of, or fear associated with, a
potentially-severe headache or migraine, such as evad-
ing commitments or making plans (81,82).
Nevertheless, except for the FAIM and HANA, all
condition-speciﬁc and most treatment-response meas-
ures also assessed the wider impact of headache on
social function and interactions, activities of daily
living and/or work. Several measures (MSQv2.1, HIT,
HIT-6, EUROLIGHT, CORS and PPMQ-R) also
assessed both the emotional burden and cognitive
impact of headache/migraine.
Three condition-speciﬁc (FAIM, MSQv2.1 and
HIT-6) and one treatment-response (PPMQ-R) meas-
ures have strong evidence of both structural validity
and reliability of internal consistency. Factor analysis
supported the uni-dimensionality of the FAIM follow-
ing completion by migraineurs, and the HIT-6 as a
measure of ‘‘headache disability’’ following comple-
tion by mixed populations. The three-domain struc-
ture of the MSQv2.1 was supported – Role
Restriction (RR), Role Prevention (RP) and
Emotional Function (EF) – following completion in
both chronic and episodic migraine populations.
However, for most measures, evidence of structural
validity or reliability of internal consistency was lim-
ited, from methodologically-poor quality studies, or
not available. Evidence of temporal stability was
also limited, and available only for the HIT, HIT-6,
M-ACT, M-TAQ, M-TOQ and PPMQ-R. There was
no evaluation of measurement error.
Five condition-speciﬁc (FAIM, MIDAS, MSQ v2.1,
HIT and HIT-6), two treatment-response (MTSM and
PPMQ-R) and two generic (SF-36 and SF-8) measures
have acceptable evidence of construct validity from
good quality studies. For the remaining measures, evi-
dence was limited, of poor methodological quality, or
not available. Methodological inadequacies included
small sample sizes and a failure to hypothesise a
priori the expected association between variables.
As reported in other reviews (18,19), there was limited
evidence of responsiveness: Just two studies (31,38)
provided acceptable, but limited, evidence for the
CORS and HIT measures. Evaluative measures require
evidence of responsiveness to demonstrate that they can
detect real change in condition over time; without such
evidence, measures should be applied with caution.
While a limitation of the review is that we have only
included evaluations in English, the context, setting and
population are important in appraising evidence of
PROM measurement and practical properties (83).
Moreover, the diversity of reviewed measures reﬂects
the wide range of assessment approaches in current
use. Reviewed studies were of adults aged 18 years
and over; with no upper age-limit imposed.
All reviewed studies excluded people with signiﬁcant
co-morbidities. We are conﬁdent that the results are
generalisable to the wider population of English-
speaking adults with headache, but may not reﬂect
the experience of adults with headache who have
signiﬁcant co-morbidities or do not speak English.
All data from included studies was double extracted
and agreement checked (KH, TM). However, the
COSMIN grading and synthesis score was applied by
a single, experienced reviewer (KH). Although applied
in several recent reviews (19,84), the grading system
itself lacks robust evidence of reliability and validity
and should therefore be interpreted with caution.
The lack of reporting guidance and signiﬁcant
heterogeneity in outcome assessment detailed in this
review highlight the importance of establishing guid-
ance on outcome reporting in this population. Future
research should seek to establish international, multi-
perspective guidance for a core set of outcomes to
include in future headache research and across routine
practice settings. The ﬁrst step in this process is to seek
consensus on which outcomes should be assessed, as a
minimum, in future clinical trials or routine practice
settings (85). Informed by recommendations from this
review, the second step is to determine the ‘‘best way’’
to assess these core outcomes.
Although many PROMs were reviewed following
their evaluation in the headache and/or migraine popu-
lation, study methodological quality was often poor
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and evidence of essential measurement properties lar-
gely unavailable or limited. Such limitations hinder
PROM data interpretation from clinical trials, audit,
or quality assurance initiatives. However, three meas-
ures – HIT-6, MSQv2.1 and the PPMQ-R – had accept-
able, and often strong, evidence of reliability and
validity following completion by patients with head-
ache (HIT-6) or migraine (HIT-6, MSQv2.1,
PPMQ-R), and are recommended for consideration in
future clinical research and routine practice settings as
measures of headache-speciﬁc impact, migraine-speciﬁc
impact, or migraine-treatment response respectively.
However, the similarity of item content across all
three measures suggests that a further exploration of
the attribution, relevance and acceptability of the
measures with representative members of the patient
population is warranted. Further comparative evidence
of widely-used generic measures and evidence of meas-
urement responsiveness of all measures is urgently
required.
Article highlights
. Despite the large number of reviewed PROMs currently used with patients with headache, most have not
involved patients in the development process and may lack relevance to the patients’ experience of headache.
Most also lack clarity with regard to measurement aim and have limited evidence of essential measurement
properties, limiting conﬁdence in data interpretation. These PROMs should be used and interpreted with
caution.
. Strong evidence of reliability and validity was reviewed for three measures, HIT-6, MSQv2.1 and the
PPMQ-R, supporting recommendation for consideration in future clinical research or routine practice
settings. However, unlike the MSQv2.1 and PPMQ-R, patients were not involved in item generation for
the HIT-6.
. The review has highlighted signiﬁcant heterogeneity in outcome reporting in headache studies, raising con-
cerns over reporting bias and limiting the conduct of systematic reviews and meta-analyses of evidence.
International multi-perspective consensus on the most important outcomes – both which outcomes and how
to assess them – is required, and can be supported by the ﬁndings from this review.
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